Turning Point Brands, Inc. (TPB): what the price assumes

In the published model solve dated 2026-Q2, anchored at $83.34, Turning Point Brands, Inc. (TPB) is priced for +8.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/TPB

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 10: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.1% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.3pp.

Reconcile: at the x-ray's 9.3% required return this reads ~17%/yr; the models below use their own rates.

How unusual the bet is: within-range

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.1%); the inversion above states its own rate.

Per-Model Detail (n=12)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Turning Point Brands pairs two slow-and-steady franchises, Zig-Zag rolling papers and Stoker's smokeless products, with a nicotine-pouch business growing 133% year over year, and modern oral now accounts for 42% of net sales.
• The regulatory gate is the defining risk: the FRE and ALP pouch brands still sit in FDA substantive review under the premarket pathway, while the only fully authorized competitors are ZYN and on! PLUS, and the 10-K warns new rules can arrive "without industry input and have significantly contributed to reduced industry sales volumes" (accession 0001437749-26-006405).
• Watch the raised full-year modern oral guidance of $280 to $300 million in gross sales, the ALP launch into 11 European markets beginning July 2026, and any FDA movement out of the fast-track pilot's review phase.

Bull Case

This is a growth-stage company wearing a tobacco company's clothes, and the classification changes how every number should be read. A mature nicotine business trading at 30.7x earnings would be expensive; a company whose newest segment more than doubled year over year is being priced for what it is becoming. The structure is deliberate: the FY2025 10-K describes the two legacy segments, "rolling papers, tubes, and related products" and cigar wraps under Zig-Zag, plus the Stoker's smokeless franchise (accession 0001437749-26-006405), as the cash-generating base, and management frames the company as positioned "to act as a consolidator within the OTP industry" with "a strong track record of enhancing our OTP business with strategic and accretive acquisitions".

The growth engine is the modern oral ramp, and its first-quarter numbers were the kind that reset a model. Net sales in the segment rose 133% year over year to $52 million (gross sales up 167% to $69 million), reaching 42% of company net sales, while consolidated revenue grew 17% to $124.3 million and adjusted EPS of $0.76 beat the $0.57 consensus. Management raised full-year modern oral guidance by roughly a quarter, to $280 to $300 million of gross sales, and ALP holds a top-five U.S. position with about a 2% share of a category still dominated by ZYN. The July 2026 launch into 11 European markets opens a second geography before the U.S. land grab has even settled.

The regulatory position, usually the bear point in nicotine, doubles as a moat here. FRE and ALP were selected into the FDA's fast-track PMTA pilot and sit in substantive review, and the company has, in its own words, "increased our investments in teams of professionals including regulatory lawyers, scientists and quality assurance processes to ensure we maintain a competitive advantage in this area". Full authorization would put TPB's brands in a club that currently contains only two products. With a safe-zone balance sheet, moderate well-covered leverage, a 5.9 current ratio, and a falling share count, the base business funds the bet without existential risk.

Bear Case

Every leg of this thesis passes through Washington. The growth engine, nicotine pouches at 42% of net sales and climbing, is a product line that cannot be legally marketed long-term without FDA authorization, and FRE and ALP remain in substantive review rather than authorized; the only pouches to have cleared the full premarket pathway are ZYN and Altria's on! PLUS. The company's own 10-K is candid about the asymmetry: regulations "are often introduced without industry input and have significantly contributed to reduced industry sales volumes and increased illicit trade", and the company "may be unable to accommodate such regulations in a cost-effective manner that allows us to continue to compete in an economically viable way" (accession 0001437749-26-006405). Add the excise-tax lever: the filing warns that higher state excise taxes or reclassification rulings "could adversely affect demand for our products". A single adverse regulatory outcome does to this stock what no competitor could.

The competition is nonetheless arriving with heavier artillery. Philip Morris, whose own filing calls ZYN "the leading smoke-free product brand in the U.S. market" (PM FY2025 10-K, accession 0001628280-26-005939), launched ZYN ULTRA in higher nicotine strengths in June 2026, a direct strike at the strength-and-format niches where FRE differentiated. Altria defends the same shelf. TPB's roughly 2% category share is a foothold, not a fortress, and the category economics will be set by companies whose marketing budgets exceed TPB's entire revenue.

Meanwhile the price has moved ahead of the cash. At 30.7x trailing earnings versus a 22x sector median and 21.3x EV/EBITDA versus 14x, the market is paying about 20 times operating income for roughly 8.7% annual operating-profit growth sustained five years, and the asset-value and earnings-power methods read the price at 2.3x and 1.9x their marks. The trailing cash flow statement does not yet cooperate: free cash flow was near zero over the trailing year, with operating cash flow far below net income and positive free cash flow in only two of four quarters. Growth explains some of that, but a nicotine company priced at a premium multiple on hopes of FDA grace, against Big Tobacco's counterattack, with thin trailing cash conversion, is a stack of correlated bets, and they all resolve through the same agency.

Valuation

At $87.41 (July 11, 2026), the market pays about 20 times company-wide operating income, embedding roughly 8.7% annual operating-profit growth for five years, a pace within what the company has recently delivered. The margin ask is nonexistent: the long-run operating margin the price requires, under 4%, sits far below the roughly 17.6% the business earns today. This is a duration-of-growth bet, and given that modern oral net sales grew 133% last quarter, the near-term trajectory clears the required pace with room to spare; the question the price poses is what happens in years three through five.

The method families divide on exactly that question. The forward-growth methods land above the price, reading it at about 0.8x their central estimate, and peer multiples roughly ratify it at 1.2x. The static frames disagree: asset-based methods read the price at 2.3x and earnings-power at 1.9x, because trailing twelve-month results, $0.48B of revenue and $0.06B of net income from a period that predates most of the pouch ramp, cannot statically carry a $1.70B market value. On trailing multiples the stock costs 30.7x earnings against a 22x sector median and 21.3x EV/EBITDA against 14x. The premium is the market's advance payment on the raised guidance, $280 to $300 million of full-year modern oral gross sales against the two legacy segments the 10-K describes as the distribution base (accession 0001437749-26-006405).

Solvency does not complicate the bet: leverage is moderate and well covered, the current ratio is 5.87, and the safe-zone balance-sheet read gives the growth investment room to run. The soft spot is cash conversion, with trailing free cash flow near zero and operating cash flow well under net income, so the earnings quality of the ramp is the number to audit each quarter. The dividend, $0.30 per common share annualized at a 10.5% payout, is symbolic; the real capital allocation is the pouch build-out, and the price already assumes it works.

Catalysts

The FDA is the calendar that matters most. FRE and ALP are in the substantive review phase of the premarket tobacco application process within the FDA's fast-track pilot for nicotine pouches. An authorization would put TPB's brands alongside ZYN and on! PLUS as the only fully cleared pouches in the U.S. market; an adverse or delayed outcome caps the growth story. There is no announced decision date, which makes every FDA communication a potential repricing event.

The operating cadence runs alongside. First-quarter 2026 results beat expectations with revenue of $124.3 million, up 17%, adjusted EPS of $0.76 versus a $0.57 consensus, and modern oral net sales up 133% to $52 million; management raised full-year modern oral guidance to $280 to $300 million of gross sales and $210 to $225 million of net sales. The next quarterly print tests whether the category's velocity holds as Philip Morris rolls out ZYN ULTRA, launched in June 2026 in 9mg and 11mg strengths, into the same convenience-store shelf space.

The international expansion opens a new front in July 2026: ALP begins entering 11 European markets, with online sales debuting in Britain, Ireland, Greece, Switzerland, and Romania. Early sell-through there, plus U.S. share progression from ALP's roughly 2% base, will indicate whether TPB's brands can scale outside their first-mover niches. Secondary watch items: cash conversion recovering toward net income as the inventory-heavy ramp matures, and any bolt-on acquisitions consistent with the consolidator posture the 10-K describes.

Peer Cohorts (Per Segment, With Filing Citations)

Zig-Zag products / Stoker's products (reported)

• MO (ALTRIA GROUP, INC.)
• FY2025 10-K: States. The program that allows for these refunds is referred to as "duty drawback." If PM USA is unable to realize duty drawback to the same extent as other manufacturers, we may be at a competitive disadvantage with respect to our ability to invest in the long-term growth of our core tobacco businesses and…
• FY2025 10-K: …companies' innovative and smoke-free products and traditional tobacco products. Illicit trade in nicotine products can take many forms, including the sale of counterfeit products; the sale of products that do not comply with the FSPTCA and FDA regulations; the sale of products in the United States that are intended…
• PM (Philip Morris International Inc.)
• FY2025 10-K: …We believe that there is full comparability between the bladed versions of IQOS and the subsequent induction versions of IQOS , and that the data from the studies conducted with the blade version of IQOS remain valid and applicable to the newer and adjacent versions of IQOS . We also produce a heat-not-burn product…
• FY2025 10-K: …portfolio with the acquisition of Swedish Match. Swedish Match's ZYN is the leading smoke-free product brand in the U.S. market. • e-Vapor products, which are battery-powered devices that produce an aerosol by vaporizing a tobacco-free liquid solution. We have developed e-liquids for our e-Vapor products with…
• RLX (RLX Technology Inc.)
• FY2025 20-F: , if we fail to implement effective measures to prevent purchases and uses of our products by the underage in accordance with announcements, guidance and regulations issued by government authorities, we may be subject to negative publicity and legal proceedings. Additionally, counterfeit and compatible products…
• FY2025 20-F: …strategies targeting the underage and the non-smoking population. Negative publicity on the health consequences of e-vapor products or other similar devices and their social impact, especially among juveniles, may also adversely affect the usage of e-vapor products. For example, a morbidity and mortality report…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.